Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Chiesi Group

    - PMLiVE

    Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study

    The trial is evaluating OHB-607 for preventing bronchopulmonary dysplasia and other complications

    - PMLiVE

    Chiesi Group invests €400m to establish biotech centre of excellence in Italy

    The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

    - PMLiVE

    Chiesi targets patient adherence via mobile app

    Initiative will see asthma and COPD patients receive device training support

    - PMLiVE

    Chiesi’s ultra-rare genetic disorder therapy wins European backing

    Lamzede is set to become the first approved therapy for Alpha-Mannosidosis

    - PMLiVE

    Chiesi Group’s Trimbow wins European licence

    European Commission approves the COPD treatment

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links